Sensei Biotherapeutics (NASDAQ:FTH) Stock Jumps 7.1% – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price was up 7.1% during mid-day trading on Tuesday. The company traded as high as $28.00 and last traded at $29.0210. Approximately 55,706 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 238,846 shares. The stock had previously closed at $27.10.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on FTH. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Robert W. Baird started coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. Guggenheim began coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They issued a “buy” rating and a $70.00 target price on the stock. Finally, JonesTrading initiated coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Stock Down 7.3%

The firm has a 50 day moving average of $31.92. The firm has a market capitalization of $643.93 million, a price-to-earnings ratio of -0.18 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. Analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current year.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Renaissance Technologies LLC lifted its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Finally, Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.